Company has initiated Phase 2 monotherapy study in trichotillomania and prepares for a Phase 2 add-on therapy study in OCD Milwaukee, Wisconsin | January 17, […]
Dr. Chad Beyer to provide nonclinical and clinical findings of the company’s first-in-class, System xc– activator Milwaukee, WI – December 5, 2018 — Promentis Pharmaceuticals, Inc., a […]
Promentis plans to initiate monotherapy and add-on therapy studies in two neuropsychiatric disorders Milwaukee, Wisconsin | November 16, 2018 — Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical […]
Dr. Chad Beyer and Michael Neary will present key scientific data on SXC-2023, a novel activator of System xc-, at the annual Society for Neuroscience meeting taking place November 3-7, 2018 in San Diego, California.
Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company developing innovative therapies for neuropsychiatric disorders, today announced that it has commenced a Phase 1 single ascending dose study for its lead compound, SXC-2023.
Promentis Pharmaceuticals, Inc., a privately-held biopharmaceutical company focused on the discovery and development of first-in-class therapies to treat central nervous system disorders, today announced it has completed a third round of equity investment totaling $26,000,000.
Promentis Pharmaceuticals, Inc., a specialty pharmaceutical company developing novel compounds for schizophrenia, Parkinson's disease and pediatric disorders including autism, announced today it has raised nearly $3 million in Series B financing.
Promentis Pharmaceuticals, Inc. announced today that it has received a Phase II Small Business Innovation Research (SBIR) award from the National Institute of Mental Health (NlMH) of the National Institutes of Health. The three-year award, totaling $1.8 million, is the continuation of a Phase I SBIR grant received previously by Promentis to develop novel compounds to treat schizophrenia.
Promentis Pharmaceuticals, Inc. announced today that it has been awarded funding by The Michael J. Fox Foundation (MJFF) to conduct pre-clinical research targeting compounds that show promise as neuroprotective agents for patients suffering from Parkinson’s disease.